• 1. An investigation on the second-order nonlinear optical response of cationic bipyridine or phenanthroline iridium(iii) complexes bearing cyclometallated 2-phenylpyridines with a triphenylamine substituent?
  David B. Cordes,Alexandra M. Z. Slawin,Stefania Righetto,Denis Jacquemin,Eli Zysman-Colman,Véronique Guerchais Dalton Trans., 2018,47, 8292-8300
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277

Recent Advances in the Study of 2-amino-1-(2-methoxyphenyl)ethan-1-ol (CAS: 54942-63-1) and Its Applications in Chemical Biology and Medicine

The compound 2-amino-1-(2-methoxyphenyl)ethan-1-ol (CAS: 54942-63-1) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties and potential therapeutic applications. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activities, and emerging applications in drug development.

Recent studies have highlighted the role of 2-amino-1-(2-methoxyphenyl)ethan-1-ol as a key intermediate in the synthesis of various bioactive molecules. Its structural motif, featuring an amino alcohol group and a methoxyphenyl ring, makes it a valuable scaffold for designing novel drugs targeting neurological and cardiovascular diseases. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a precursor for developing selective serotonin reuptake inhibitors (SSRIs) with improved pharmacokinetic profiles.

In addition to its synthetic utility, 2-amino-1-(2-methoxyphenyl)ethan-1-ol has shown promising biological activities in preclinical models. Research conducted at leading pharmaceutical institutions has revealed its potential as an anti-inflammatory and neuroprotective agent. Mechanistic studies indicate that the compound modulates key signaling pathways, including the NF-κB and MAPK cascades, which are implicated in chronic inflammatory conditions and neurodegenerative disorders.

Another area of active investigation is the compound's role in cancer therapeutics. A recent publication in Bioorganic & Medicinal Chemistry Letters reported that derivatives of 2-amino-1-(2-methoxyphenyl)ethan-1-ol exhibit potent inhibitory effects on certain cancer cell lines, particularly those associated with breast and prostate cancers. These findings underscore the compound's potential as a lead structure for developing targeted anticancer agents.

From a methodological perspective, advances in analytical techniques have enabled more precise characterization of 2-amino-1-(2-methoxyphenyl)ethan-1-ol and its derivatives. High-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy have been instrumental in elucidating its molecular interactions and stability profiles. Furthermore, computational modeling approaches, such as molecular docking and dynamics simulations, have provided valuable insights into its binding modes with biological targets.

Despite these promising developments, challenges remain in optimizing the compound's bioavailability and reducing potential off-target effects. Ongoing research efforts are focused on structural modifications to enhance its drug-like properties while maintaining its therapeutic efficacy. Collaborative initiatives between academic and industrial researchers are expected to accelerate the translation of these findings into clinical applications.

In conclusion, 2-amino-1-(2-methoxyphenyl)ethan-1-ol (CAS: 54942-63-1) represents a compelling case study in the intersection of chemical biology and drug discovery. Its multifaceted pharmacological profile and synthetic versatility position it as a valuable asset in the development of next-generation therapeutics. Future research directions may include exploring its applications in combination therapies and investigating its mechanisms of action at the molecular level.

• 3600-87-1(ST 1059(Desglymidodrine))
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)